Navigation Links
PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it
Date:7/13/2009

cut, and colleagues conducted an anonymous online survey of 690 adults to measure "dementia literacy," that is, their knowledge and beliefs that may assist in the recognition, management, or prevention of Alzheimer's.

Mean age of the population was 50 years, the range was 30-85 years; 76% of respondents were female. Ninety-four percent (94%) of participants were from the United States, with the remaining 6% from other English-speaking countries. The sample was relatively wealthy, with 18% of respondents making more than $200,000 per year at the peak of their careers, and well-educated, with 87% of respondents having completed at least 1-3 years of college.

The researchers found that 64% of study participants incorrectly indicated no association between Alzheimer's and obesity or high blood pressure. Sixty-six percent (66%) did not know that high stress is a risk factor for dementia, and 34% did not know that physical exercise is a protective factor.

On the positive side, nearly all study participants (94%) correctly indicated that Alzheimer's is not normal aging, and is not completely based on genetics.

"Our data suggest that American adults have limited knowledge and a poor understanding of factors that have been demonstrated to increase risk for Alzheimer's, such as obesity, high blood pressure, and other heart health risk factors," Jackson said. "They also didn't know much about protective factors against Alzheimer's, such as physical exercise, relative to the strength of the available research evidence."

"We need more education programs and opportunities, across all demographic groups, focusing on behaviors that modify your risk for developing Alzheimer's disease," Jackson added.

PTSD Linked to Nearly Double Dementia Risk in Veterans

Post-traumatic stress disorder (PTSD) is common among veterans returning from com
'/>"/>

SOURCE Alzheimer's Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
2. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
3. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
4. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion
7. Increased Mortality Associated With Nocturia
8. Obesity Associated With Higher Risk for Urinary Tract Infections
9. Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea
10. Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
11. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...swire/ -- ,, Reportlinker.com announces that a ...alogue. ,, Global Markets for Breast Biopsy De...164741/Global-Markets-for-Breast-Biopsy-Devices-20...p;utm_campaign=prnewswire ,, The global marke...oaded core needle market and vacuum assisted breas...
(Date:11/20/2009)...re-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX )...ef Executive Officer, and Greg Browne, Chief Finan...r Jaffray Health Care Conference in New York on We...nference session and webcast will be audio only an...ay will host a webcast of the presentation live an...
(Date:11/19/2009)...ewswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) t...nced secondary offering of 20,000,000 of its ordin...share. The selling shareholders include funds aff...anking, J.P. Morgan Partners (advised by CCMP Capi...er institutional investors and members of the Comp...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 1NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 2Long Term Back Pain Not Inevitable Study Finds 59075 1Long Term Back Pain Not Inevitable Study Finds 59075 2Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 1Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 2
...onference Call on Monday, April 14, at 8:30 a.m. E...m.com , CARLSBAD, Calif., April 14 Isis,Pharmace...l results from its,ongoing Phase 2 open-label exte...amilial hypercholesterolemia (FH). In FH patients ...e safety profile of the drug,continues to be encou...
...3 Researchers from the,Barbara Ann Karmanos Cance...owing that adding curcumin or resveratrol to conve...ing the growth of chemo-resistant colon cancer,cel...merican Association,for Cancer Research (AACR) Ann...om.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITU...
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:11/20/2009).... 20 Following a recall by Unileve...from sale Shedd,s Country Crock ® Side Dishes...Crock ® Side Dishes DELUXE Four Cheese Pasta ...following code dates and UPCs are affected: ,, ...heddar Broccoli Rice 21 oz, UPC 027400218316, Best...
(Date:11/20/2009)...PRNewswire-USNewswire/ -- The American Dental Asso...dministration (FDA) to establish appropriate class...iting concern about the safety of whitening produc... of professional consultation or examination by a ... of chemically based tooth whitening or bleaching ...
(Date:11/20/2009)...., Nov. 20 Samuel Gladd...ine what it means to be "happy" during the holiday...cialty in family counseling and chair of the Depar...dding says research shows that it is the pressure ...epression during the holidays. ,, That,s why he...
(Date:11/20/2009)...ne November 20 in the Journal of the National Can... hopes that often appear in news coverage of cance...th the media and journals to help alleviate the pr...n Woloshin, M.D., M.S., of Center for Medicine and...olicy and Clinical Practice in New Hampshire, and ...
(Date:11/20/2009)...ber 20, 2009Emergency medical service (EMS) provid...00 cardiac arrests each year. Only 5 to 10 percen.... Better quality cardiopulmonary resuscitation (C...ssociated with better patient outcome. The Resusc...linical research network to study prehospital trea...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...ch 5 Peregrine Pharmaceuticals, Inc. (Nasdaq: P...ancial results for the third quarter of fiscal yea... host a conference call and webcast to discuss the... 2009 and will review recent operating highlights....
...eives EU and US Approvals for Intravenous Formulat...l Temozolomide Sachet Presentation , , KENILWORTH...: SGP ) today announced that the European Commis...emozolomide is marketed as TEMODAL(R) in the EU an...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) tod...l year 2008 financial results after the NASDAQ Glo...at same afternoon, Jack Lief, Arena,s President an.... Eastern Time (2:00 p.m. Pacific Time) to discuss...
...., March 5 Smith & Nephew Inc,s Advanced Woun...y announced the U.S. launch of its next Negative P...SYS (TM) GO, designed to address the needs of cli...wound care. The U.S. Food and Drug Administration ...
...acquisition of NMHC drives GAAP earnings per share...4 2008, up from $6.5 million in Q4, 2007, ,...C Health Solutions Corp. ("SXC" or the "Company") ... in U.S. dollars unless otherwise indicated. , "20...
...e demand for a reliable, non-invasive, efficient a...s, lifestyles is boosting interest in bone growth ...t is however still small, as clinicians have felt ... research papers to substantiate the efficacy of t...
Other Medicine News:Health News:Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 2Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 2Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 4Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 2Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: